BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. FDA Investigational New Drug (“IND”)-enabling pharmacology studies. TD-0148A is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations.
"Following our recent acquisition of the assets of Transcend Biodynamics, we are excited to be initiating the IND-enabling studies for TD-0148A. We look forward to working with Eurofins Discovery to bring this treatment to patients as quickly as possible as we prepare for our IND and trials," said BetterLife's Chief Executive Officer, Dr. Ahmad Doroudian.

Related Keywords

Vancouver ,British Columbia ,Canada ,Ahmad Doroudian ,Eurofins Cerep ,Wendy Parenteau ,Betterlife Pharma ,Eurofins Biopharma Services ,Marketing Communications ,Nuclear Hormone Receptors ,Betterlife Pharma Inc ,Qlife Pharma ,Eurofins Discovery ,New Drug ,Lysergic Acid Diethylamide ,Transcend Biodynamics ,Chief Executive Officer ,Ion Channels ,Director Marketing ,Other Otc Betrf ,Better Life ,Betr ,Otcqb Betrf ,Psychedelic Therapy ,Npau ,Biotech ,வான்கூவர் ,பிரிட்டிஷ் கொலம்பியா ,கனடா ,வெண்டி பெற்றோர் ,சந்தைப்படுத்தல் தகவல்தொடர்புகள் ,வாழ்க்கை பார்மா ,புதியது மருந்து ,தலைமை நிர்வாகி அதிகாரி ,அயன் சேனல்கள் ,இயக்குனர் சந்தைப்படுத்தல் ,சிறந்தது வாழ்க்கை ,சைகடெலிக் சிகிச்சை ,பயோடெக் ,